'We have delivered robust growth across all segments. This, we believe, is a trend that holds goods prospects for the year ahead,' Biocon chairperson Kiran Mazumdar Shaw said in a statement.

Operating profit grew 45 percent to Rs.101 crore, while operating margins excluding that of AxiCorp were sustained at 32 percent.

'We are making excellent progress on the research front with several programmes approaching a licensing potential. Our recently announced partnership deal with Mylan positions us amongst the front-runners to address the emerging global market opportunity for bio-generics,' Shaw said.